Gilead Sciences has agreed to purchase the remainder of improvement accomplice Arcellx in a deal that values the biotechnology firm at about $7.8 billion at closing.
Source link
Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion
Related Posts
Trump Imposes New Tariffs to Sidestep Supreme Court Ruling
President Trump is including a brand new 10 p.c tariff on almost all imports to the USA, following a Supreme…
Perplexity plans IPO in 2028 as Anthropic, OpenAI prepare listings
Aravind Srinivas, chief government officer of Perplexity AI Inc., through the Bloomberg Tech convention in San Francisco, California, US, on…
Best Tested Walking Pads (2025): Urevo, WalkingPad, Sperax
Most Versatile {Photograph}: Kristin Canning Lifesmart TM2202 3-in-1 Treadmill For those who’re not eager on shopping for a standing desk,…